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K e y  M e s s a g e s 
1. In patients suspected to have tuberculosis, a valid 
molecular test result was obtained in 94.3% and 
88.3% of patients for the rpoB and katG loci, 
respectively, for prediction of drug susceptibility.
2. Molecular testing based on katG and rpoB 
enabled rapid detection of Mycobacterium 
tuberculosis resistance in 46.8% and 87.5% of 
patients infected with isoniazid- and rifampicin-
resistant strains, respectively. The same number 
of patients infected with resistant strains with 
mutations in katG and rpoB were detected using 
the MTBDRplus line probe assay. The combined 
use of katG and inhA regulatory region in the 
MTBDRplus line probe assay increased the 
proportion of patients identified with INH-
resistant MTB strains to 72.3%.
Molecular tests for rapid detection of rifampicin 
and isoniazid resistance in Mycobacterium 
tuberculosis
Introduction
Multidrug-resistant tuberculosis (MDR-TB) 
often entails prolonged treatment and the use of 
more toxic drugs. It is also associated with higher 
rates of treatment failure and death. The World 
Health Organization category I regimens for the 
management of MDR-TB are inadequate. In British 
Medical Research Council studies, only three of 
the 11 patients with MDR-TB were cured when 
prescribed standard treatment. Early recognition of 
resistance and administration of two or more drugs 
have improved patient outcome. It is important to 
reduce the turn-around time for reporting anti-
tuberculosis drug susceptibility. Cultures are the gold 
standard for susceptibility testing, but they are limited 
by the pre-requisite for a pure growth from clinical 
specimens. As the mechanisms for rifampicin (RIF) 
and isoniazid (INH) resistance in many isolates of 
Mycobacterium tuberculosis (MTB) are predictable, 
molecular methods are used for direct detection 
of RIF and INH resistance. This study evaluated 
genotypic tests to detect RIF and INH resistance in 
MTB in clinical specimens. The potential impact of 
implementing molecular tests to detect RIF and INH 
resistance in MTB was also assessed.
Methods
This study was conducted from April 2006 to June 
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2009. Patients were prospectively identified from 15 
participating centres at the tuberculosis and chest 
unit of the Department of Health, the Grantham 
Hospital, the Kowloon Hospital, and the Haven of 
Hope Hospital. Adult patients suspected to have 
active tuberculosis and were at risk of infection with 
INH- and/or RIF-resistant strains were enrolled. 
Clinical specimens (sputum or other appropriate 
samples) were tested by polymerase chain reaction 
(PCR) assays specific for IS6110, rpoB, and katG. 
The amplicons were sequenced to detect resistance 
mutations. PCR and sequencing were conducted 
on a weekly basis. Specimens with resistant strains 
were also tested by the MTBDRplus and the INNO-
LiPA Rif.TB line probe assays. Acid-fast bacillus 
smear and mycobacterial culture were performed by 
conventional methods. 
Results
Patient demographics and sensitivity of the 
PCR assays
A total of 820 specimens (>90% respiratory) were 
obtained from 720 patients. In 596 (82.7%) patients, 
the culture was positive for MTB. Using the culture 
and susceptibility testing result as reference, the 
overall sensitivity of the IS6110, rpoB, and katG PCR 
assays was 98.9%, 95.9%, and 88.7%, respectively 
(Table 1). 94.3% (562/596) and 88.3% (526/596) of 
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3. The rapid tests improved patient management 
by enabling earlier admission, more timely use 
of World Health Organization category IV anti-
tuberculosis regimens and discontinuation of 
ineffective drugs.
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patients had valid molecular test results for the rpoB 
and katG loci, respectively.
 Susceptibility testing revealed that 50 patients 
were infected with strains resistant to INH and/
or RIF, including MDR-TB (INH-R/RIF-R) [n=13], 
INH-R/RIF-S (n=34), and INH-S/RIF-R (n=3). The 
remaining 542 MTB isolates were susceptible to 
both INH and RIF. 
Correlation between susceptibility testing 
and rpoB mutations
Among 562 valid molecular rpoB test results, the 
concordance rate with susceptibility testing was 
99.5% (559/562). Mutations were found in codons 
531, 533, 526, and 516 within the rpoB hotspot region. 
The discordant results involved three patients with 
RIF-susceptible isolates and one of two mutations 
(L533P and H526N). All rpoB mutations, including 
the three discordant results, were confirmed by 
testing the purified isolates. Fourteen (87.5%) of 16 
patients infected with RIF-resistant strains were 
detected by the PCR-sequencing method. The 
detection rate for rpoB mutation was the same using 
the GenoType MTBDRplus test.
 Among 527 valid molecular katG test results, 
the concordance rate with susceptibility testing 
was 97.2% (512/527). Our katG PCR assay could 
rapidly detect resistance in only 22 (46.8%) of the 
47 patients infected with INH-resistant strains. The 
same number (ie 22) of katG mutations was detected 
using the GenoType MTBDRplus test, which also 
detected an additional 12 patients with mutations 
in the promoter region of inhA. Therefore, INH 
resistance was correctly predicted by the GenoType 
MTBDRplus test in 34 (72.3%) of the 47 patients.
Impact on patient management
Overall, 50 patients had a positive culture for MTB 
isolates resistant to INH and/or RIF. Susceptibility 
testing revealed that 34 isolates were resistant 
to INH alone, three to RIF alone, and 13 to both 
INH and RIF (ie MDR-TB). 92% and 80% of the 
50 patients had a valid result for rpoB and katG 
mutations, respectively. The genotypic results 
according to PCR-sequencing correctly predicted 
rpoB resistance mutations in 15 specimens and 
katG resistance mutations in 22 specimens. These 
mutations involved 32 patients and the correlation 
with the susceptibility result is summarised in Table 
2. The mean±standard deviation (SD) turnaround 
time was 10.2±5 days for rpoB and 9.5±4.8 days for 
katG. This was significantly shorter than the interval 
between first sputum specimen and susceptibility 
test reporting (15.4±5.4 weeks). This enables earlier 
* In 13 patients, the culture was positive for non-tuberculous mycobacteria
TABLE 1.  Comparative sensitivity of three polymerase chain reaction (PCR) assays for detection of Mycobacterium tuberculosis (MTB)
Parameter No. (%) of patients
Positive results rpoB mutation katG Thr315
IS6110 PCR rpoB PCR katG PCR Present Absent Indeterminate Present Absent Indeterminate
MTB culture-positive (n=596) 590 (98.9) 572 (95.9) 529 (88.8) 17 545 10 21 505 3
Smear-positive (n=538) 538 (100) 532 (98.8) 503 (93.5) 16 512 4 19 482 2
Smear-negative (n=58) 52 (89.6) 40 (68.9) 26 (44.8) 1 33 6 2 23 1
MTB culture-negative (n=124)* 66 54 41 0 53 1 0 41 0
Total 656 (91.1) 626 (86.9) 570 (79.2) 17 598 11 21 546 3
TABLE 2.  Correlation between polymerase chain reaction–sequencing for rpoB and katG mutations and susceptibility testing in 32 patients infected 
with Mycobacterium tuberculosis resistant to isoniazid and/or rifampicin
Genotypic result obtained by testing of 
respiratory specimens
No. of phenotypic result obtained by susceptibility testing
rpoB katG Isoniazid-resistant (n=17) Rifampicin-resistant (n=3) Multidrug-resistant (n=12)
Mutated Mutated - - 4
Mutated Wild type - 3 4
Indeterminate Mutated - - 1
Mutated Indeterminate - - 3
Wild type Mutated 17 - -
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patient isolation, admission for treatment, and 
discontinuation of inactive drugs (Table 3).
Discussion
In Hong Kong, diagnostic PCR is useful to detect 
MTB in clinical specimens.1 This study extended 
this by inclusion of two PCR assays specific for 
rpoB and katG genes to determine whether there 
were mutations associated with resistance to RIF 
and INH. Using culture and drug susceptibility 
results as reference, 94.3% and 88.3% of patients 
had valid molecular test results for the rpoB and 
katG loci, respectively. The result for both rpoB and 
katG was highly concordant with the conventional 
susceptibility result.2
 As RIF and INH resistance could occur as a 
result of mutations in multiple gene loci, the specificity 
of molecular assays (as compared with susceptibility 
testing) would not be 100%. For RIF, a high degree of 
concordance between mutations in the rpoB hotspot 
region (codon 507-533) and phenotypic resistance 
was found. A rapid diagnosis was made for 87.5% of 
patients infected with RIF-resistant strains, as more 
than 96% of RIF-resistant strains have mutations 
in this region.3 In another three patients infected 
with phenotypic RIF-susceptible strains, the rapid 
test identified rpoB mutations (L533P or H526N), 
which were uncommon. The molecular assay results 
were reliable because identical mutations were 
confirmed by testing the isolates. These infrequent 
rpoB mutations may cause weak resistance to RIF 
and have the potential to cause highly discordant 
RIF susceptibility results, even when tested under 
proficiency evaluation settings by the Supra-
National Tuberculosis Reference Laboratories.4 The 
MTBDRplus insert also indicated that the L533P 
mutation may be RIF-susceptible in susceptibility 
testing. Nonetheless, both L522P and H526N have 
been reported to cause high-level RIF resistance 
and to occur in MDR-TB strains.5 Further studies 
to assess the clinical significance of these low-level 
resistant isolates are necessary.
 Unlike RIF resistance, the katG PCR assay 
could provide rapid diagnosis in only 22 (46.8%) of 
the 47 patients infected with INH-resistant strains. 
The same number of katG mutations was detected 
by the MTBDRplus assay. The inhA promoter 
region was included in the MTBDRplus assay as 
an additional target. This enabled detection of an 
additional 12 patients with INH-resistant infection. 
Thus, the MTBDRplus assay could rapidly detect 
INH resistance in 34 (72.3%) of the 47 patients. 
38 of the 47 INH-resistant isolates were found to 
have mutations in the katG gene and/or the inhA 
regulatory region. Thus, even if the PCR assay was 
100% sensitive in detecting mutations in katG and 
the promoter of inhA in clinical specimens, direct 
testing would at best identify 80.9% (38/47) of INH-
resistant infections. To improve the sensitivity 
further, it is necessary to include other gene target 
in molecular assays. A tuberculosis drug resistance 
TABLE 3.  Potential impact of molecular testing for Mycobacterium tuberculosis resistance mutations on patient management for seven representative 
cases
Case 
No.
Sex/
age 
(years)
History 
of 
tuber-
culosis
Risk factors 
for resistant 
tuberculosis
Genotypic test on sputum Anti-tuberculosis 
treatment
Remarks
IS6110 rpoB katG gyrA At testing After 
testing
26 M/30 Yes Multiple treatment 
in China
Positive S531L S315T Mutated None Category IV Multidrug-resistant tuberculosis (MDR-TB); 
individualised category IV treatment started 1 
week after patient presentation
11 M/66 No Persistent smear 
positivity 
Positive WT S315T - Category I Stop 
isoniazid
Test result contributed to individualised 
regimen decision
14 F/48 Yes Previous treatment 
in China
Positive D516A S315N - Category II Category IV MDR-TB; test result contributed to 
individualised regimen decision
28 F/50 No - Positive S531L WT - Category I Category IV Polydrug resistant tuberculosis; test result 
contributed to individualised regimen 
decision
29 M/30 No Extensive disease Positive S531L Indeterminate - Category I Category IV MDR-TB; patient admitted for individualised 
treatment because of test result
45 F/37 Yes Failed category I 
regimen
Positive S531L WT Mutated Category 
IV
Category IV Extensively drug-resistant tuberculosis; test 
result contributed to individualised regimen 
decision
50 M/70 Yes Failed category I 
regimen
Positive D516V Indeterminate - Category I Category IV MDR-TB; culture and sensitivity testing 
was delayed because of mixed growth of 
M tuberculosis and M gordonae; test result 
contributed to individualised regimen decision
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database has been established.5 The INH-resistant 
strains with wild type katG and promoter region 
in inhA may have mutations in the katG outside 
the fragment that was sequenced, within the inhA, 
intergenic region of oxyR-ahpC or other genes. 
Conclusions
The molecular test result is valid in most patients 
with suspected and confirmed tuberculosis. The 
test result for rpoB and katG is reliable and highly 
concordant with results using culture isolates. 
Molecular testing enables better management of 
patients infected with drug-resistant tuberculosis.
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